AbbVie Aktie Vergleich und Anlage Chancen

If you're considering investing in AbbVie, it's essential to understand the company's performance and growth prospects. AbbVie's stock has consistently outperformed the market, with a 5-year average annual return of 10.3%.

The company's portfolio is diversified across various therapeutic areas, including immunology, oncology, and virology. This diversification has helped AbbVie navigate market fluctuations and maintain a strong financial position.

AbbVie's revenue has been steadily increasing, reaching $48.8 billion in 2020, a 12.6% growth from the previous year.

Related reading: Abbvie Market Cap

As we dive into the world of AbbVie's fundamentals, let's take a closer look at their financials in USD.

The revenue per share has been steadily increasing, reaching $32.65 in 2022 and is expected to be around $31.77 in 2024.

One key metric to consider is the Price-to-Earnings (P/E) ratio, also known as KGV. In 2022, AbbVie's KGV was 24.27, which is a significant increase from 2021.

Let's take a look at the earnings per share (Gewinn je Aktie) over the past few years: $6.48 in 2021, $6.66 in 2022, and a decrease to $2.74 in 2023.

For your interest: Abbvie Earnings Report

Dividend yield has been a consistent aspect of AbbVie's fundamentals, ranging from 3.56% in 2023 to 3.56% in 2025e.

Here's a summary of AbbVie's dividend per share (Dividende je Aktie) over the years: $5.31 in 2021, $5.71 in 2022, $5.99 in 2023, and $6.29 in 2024, with a projected $6.56 in 2025e.

A unique perspective: Abbott Labs Dividend

Derivatives are a type of financial instrument that can be used to hedge against potential losses or gains in a portfolio. They are often used by investors to manage risk.

Abbvie, the parent company of Abbvie Aktie, has a significant presence in the derivatives market, with a wide range of products available to investors. These products include options, futures, and swaps.

Derivatives can be used to speculate on the future price of a stock, such as Abbvie Aktie. For example, an investor might buy a call option that gives them the right to buy a share of Abbvie Aktie at a specified price.

Broaden your view: Haleon Share Price Uk Pounds

The use of derivatives can be complex and requires a good understanding of the underlying market and the risks involved. It's essential to do your research and consult with a financial advisor before making any investment decisions.

Abbvie Aktie has a relatively high beta, which means that its stock price can be more volatile than the overall market. This can make it a more attractive option for investors who are looking to use derivatives to speculate on price movements.

Investors should carefully consider their risk tolerance and investment goals before using derivatives to trade Abbvie Aktie. It's also essential to have a solid understanding of the underlying market and the potential risks involved.

Expand your knowledge: Abbvie Stock 10 Year Investment Return

Let's take a look at the performance of AbbVie's stock compared to the S&P 500 index.

The S&P 500 index has seen a performance of +1.62% in the given period.

AbbVie's stock has outperformed the S&P 500 index with a performance of +1.46%.

In the last month, the S&P 500 index has seen a performance of +0.78%.

AbbVie's stock has shown an impressive growth of +7.44% in the last month.

Here's a summary of the performance comparison:

The EBIT margin of AbbVie Aktie stands at 10.69%, indicating a strong profitability.

This margin is a testament to the company's efficient operations and pricing strategy.

AbbVie's Gesamtkapitalrendite (total capital return) is 5.32%, which is a respectable return on investment.

In terms of valuation, the Eigenkapitalrendite (equity return) is an impressive 124.54%.

The company's revenue has reached 56.3 billion EUR, a significant milestone in its growth journey.

AbbVie's market capitalization is substantial, with 1.8 billion shares outstanding.

Each employee contributes to the company's revenue, with an average of 885,672 EUR per employee.

The company's EBIT (operating profit) stands at 5.2 billion EUR, a substantial profit from its operations.

The net income after taxes is 4.2 billion EUR, a significant profit that benefits the shareholders.

You might like: Abbvie Annual Revenue

The rating of AbbVie's stock is a crucial aspect to consider when deciding whether to invest. TheScreener-Ratings have given AbbVie three out of four stars since August 12, 2025.

Analyst sentiment has been neutral, with some analysts previously being negative. However, the last significant analyst signal was negative and occurred on August 12, 2025, when the stock price was $198.64.

The current rating is based on the company's growth potential and other criteria, and it appears that the stock is currently undervalued. The expected price-to-earnings ratio (KGV) for 2029 is 12.32.

Here's a breakdown of the rating:

The overall rating of AbbVie's stock is a good indicator of its potential for growth and stability. With a current rating of three out of four stars, it's worth considering the stock as a potential investment opportunity.

As an investor, it's essential to know who owns the shares of AbbVie. The company is primarily owned by institutional investors, with The Vanguard Group, Inc. holding a significant 9.53% stake.

The largest shareholder of AbbVie is actually the company's own shareholders, with a staggering 69.74% of shares held by them. This is known as the freefloat percentage, which is a measure of the percentage of shares available for public trading.

The institutional investors in AbbVie are a diverse group, with several large investment firms holding significant stakes. The Vanguard Group, Inc. is the largest institutional investor, followed by BlackRock Fund Advisors and SSgA Funds Management, Inc.

Here's a breakdown of the top shareholders of AbbVie:

It's worth noting that individual investors hold a relatively small percentage of shares, with 25.29% of shares held by them.

The AbbVie Aktie chart is a great place to start when analyzing the stock. You can find current analyses and insights on AbbVie and other securities on the website.

The S&P 500 has performed well, with a 1.62% increase in the current period. AbbVie, on the other hand, has seen a 1.46% increase.

To better understand the AbbVie Aktie, you can use technical analysis to interpret the stock's price movements. This can help you identify potential trends and make informed trading decisions.

The AbbVie Aktie has shown a significant increase in the last month, with a 7.44% gain. This is a notable trend that investors should consider.

Here's a comparison of AbbVie's performance with the S&P 500:

If you're looking for similar companies to AbbVie, you might want to consider Ironwood Pharmaceuticals, which has a price of $1.48 USD and a change of -4.52%.

Ironwood Pharmaceuticals is not the only option, however. Merck, with a price of 121.40 EUR and a change of 0.37%, is another company worth considering.

Roche, priced at 309.15 CHF with a change of 0.49%, is also a similar company to AbbVie.

Here's a list of similar companies to AbbVie, along with their prices and changes:

The Basic Data of AbbVie Aktie is a crucial aspect to understand before investing. The ISIN, or International Securities Identification Number, of AbbVie Aktie is US00287Y1091.

This unique identifier is used globally to identify the stock. The symbol for AbbVie Aktie is ABBV.

AbbVie Aktie is a type of stock, specifically an Aktie. The currency of AbbVie Aktie is USD, or United States Dollars.

AbbVie Aktie is listed in the United States of America. It's not part of any specific index, but it does fall under the healthcare supersector.

Here are the key details of AbbVie Aktie at a glance:

The company behind AbbVie Aktie is AbbVie Inc.

In recent news, AbbVie's stock price has been on the rise due to strong earnings reports.

The company's pharmaceuticals segment has been a major contributor to its success, with sales increasing by 12% in the past quarter.

AbbVie's acquisition of Botox-maker Allergan has also been a significant factor in its growth.

The company's pipeline is filled with promising new treatments, including a potential cure for a rare genetic disorder.

AbbVie's commitment to research and development has resulted in numerous breakthroughs in the field of medicine.

The company's focus on innovation has led to the development of new treatments for conditions such as rheumatoid arthritis and psoriasis.

AbbVie's stock price has been boosted by its strong financial performance, with the company reporting a 15% increase in revenue in the past year.

A different take: Abbvie Company Profile

You can invest in AbbVie Aktie through LYNX, which offers access to national and international markets with fair and transparent fees. With a brokerage account through LYNX, you can trade AbbVie Aktie and other listed companies worldwide.

Trading on LYNX's robust platform gives you a direct connection to home markets, allowing you to profit from high trading volumes and tight spreads. This platform also provides professional trading tools to support your investment decisions.

Be cautious when trading with short positions, like AbbVie Aktie, as it comes with significant risks, including potentially unlimited losses.

Investing can seem daunting, but it doesn't have to be. To get started, you'll want to explore your options for buying stocks.

You can buy stocks through various exchanges, with real-time updates available to keep you informed. This allows you to make timely decisions based on current market conditions.

To make the most of your investment, consider using a chart and signal analysis tool to track performance and identify trends.

Before making a purchase, take a closer look at the company's financials, including their balance sheet and income statement.

Insider trades can also provide valuable insights into a company's future prospects.

To optimize your investment, you may want to consider a dividend calculator to determine the potential returns on your investment.

Here are some key tools to consider when buying stocks:

You can trade AbbVie shares with a LYNX account, which offers access to a wide range of globally listed companies at fair and transparent fees.

With LYNX, you can trade shares directly on their home exchanges, benefiting from high trading volumes and tight spreads.

Trading with LYNX is done through a powerful and stable trading platform that provides professional tools to support your investment decisions.

You can also trade on falling markets and open short positions, but be aware that this comes with unique risks and you should only invest what you can afford to lose.

Trading with LYNX offers access to national and international exchanges, allowing you to trade shares like AbbVie's at their home markets.